Link to Original Article CMS to Test ‘Outcome-Aligned Payments’ for Tech-Supported Care Organizations participating in ACCESS Model will receive recurring payments for managing traditional Medicare
Regenerex Pharma, Inc. Enters Into Binding Supply and Development Agreement with Holista Colltech Ltd. Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound
New Wound Healing Breakthrough With Ovine Nano-Collagen QBx™ Integration July 31, 2025- Las Vegas, NV- Regenerex Pharma, Inc (OTC: RGPX), a leading innovator in advanced
Originally published: Regenerex ArticleDownload PDF Author: Regenerex Summary: Accelerex is a sterile wound ointment with the patented active ingredient QBX, which is designed to regulate
As posted on diabeticfootonline.com by David G. Armstrong A recent meta-analysis, published in Wound Repair and Regeneration, systematically examined healing rates for diabetic neuropathic foot ulcers
2024 Growth Strategy and Product Launch to Reset the Wound Bed Space and Accelerate the Healing Process in Chronic Wounds with 95% Success Rate Sept
Originally Published: Dermagenics Inc.Download PDF Author: Dermagenics Inc. Summary: This document, “The Art of Balancing the wound micro-environment,” by M.J. Hoekstra and B. Willemsteijn, discusses
Originally published: (2010) 3M Corporation3M and Tegaderm are trademarks of 3M. Used under license in Canada. © 2010, 3M. All rights reserved. 1006-01874EDownload PDF Authors:
Originally Published: Dermagenics Inc.Download PDF Author: J.A. van Loon Summary: This report summarizes the pre-market clinical evaluation and post-market clinical follow-up (PMCF) data for Tegaderm
Originally Published: Mid-South Foot and Ankle SpecialistsDownload PDF Author: Christopher L. Hendrix, DPM, FACFAS Summary: This file presents several case studies on the use of
Regenerex Pharma, Inc. was incorporated in 2021. Regenerex has corporate offices located in Gordansville, Tennessee and a manufacturing facility in Memphis, Tennessee.
